A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Major Surgery

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Major Surgery

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Modimelanotide (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 May 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top